President Joe Biden is zeroing in on the policy goals closest to his heart now that he's no longer seeking a second term, visiting New Orleans on Tuesday to promote his administration's "moonshot" initiative aiming to dramatically reduce cancer deaths.
The president and first lady Jill Biden toured medical facilities that receive federal funding to investigate cancer treatments at Tulane University, where researchers demonstrated using a piece of raw meat how they are working to improve scanning technology to quickly distinguish between healthy and cancerous cells during surgeries.
The pair then championed the announcement of $150 million in awards from the Advanced Research Projects Agency for Health. Those will support eight teams of researchers around the country working on ways to help surgeons more successfully remove tumors from people with cancer. It brings the total amount awarded by the agency to develop breakthrough treatments for cancers to $400 million.
Cancer surgery “takes the best surgeons and takes its toll on families,” Biden said. He said the demonstration of cutting-edge technology he witnessed would offer doctors a way to visualize tumors in real time, reducing the need for follow-on surgeries.
Get top local stories in DFW delivered to you every morning. >Sign up for NBC DFW's News Headlines newsletter.
“We’re moving quickly because we know that all families touched by cancer are in a race against time,” Biden said.
The teams receiving awards include ones from Tulane, Dartmouth College, Johns Hopkins University, Rice University, the University of California, San Francisco, the University of Illinois Urbana-Champaign, the University of Washington and Cision Vision in Mountain View, California.
U.S. & World
Before he leaves office in January, Biden hopes to move the U.S. closer to the goal he set in 2022 to cut U.S. cancer fatalities by 50% over the next 25 years, and to improve the lives of caregivers and those suffering from cancer.
“I’m a congenital optimist about what Americans can do," Biden said. “There’s so much that we’re doing. It matters”
Experts say the objective is attainable — with adequate investments.
“We’re curing people of diseases that we previously thought were absolutely intractable and not survivable,” said Karen Knudsen, CEO of the American Cancer Society and the American Cancer Society Cancer Action Network.
Cancer is the second-highest killer of people in the U.S. after heart disease. This year alone, the American Cancer Society estimates that 2 million new cases will be diagnosed and 611,720 people will die of cancer diseases.
Still, "if all innovation ended today and we could just get people access to the innovations that we know about right now, we think we could reduce cancer mortality by another 20 to 30%,” Knudsen said.
The issue is personal enough for Biden that, in his recent Oval Office address about bowing out of the 2024 campaign, the president promised to keep fighting for “my cancer moonshot so we can end cancer as we know it."
"Because we can do it,” Biden said then.
He said in that speech that the initiative would be a priority of his final months in office, along with working to strengthen the economy and defend abortion rights, protecting children from gun violence and making changes to the Supreme Court, which he called “extreme" in its current makeup during a recent event.
Both the president and first lady have had lesions removed from their skin in the past that were determined to be basal cell carcinoma, a common and easily treated form of cancer. In 2015, their eldest son, Beau, died of an aggressive brain cancer at age 46.
“It’s not just personal," Biden said Tuesday. "It’s about what’s possible.”
The president's public schedule has been much quieter since he left the race and endorsed Vice President Kamala Harris, making Tuesday's trip stand out.
Advocates have praised Biden for keeping the spotlight on cancer, bringing stakeholders together and gathering commitments from private companies, nonprofit organizations and patient groups.
They say that the extra attention the administration has paid has put the nation on track to cut cancer death rates by at least half, preventing more than 4 million deaths from the disease, by 2047. It has done so by bolstering access to cancer treatments and reminding people of the importance of screening, which hit a setback during the coronavirus pandemic.
“President Biden’s passion and commitment to this effort has made monumental differences for the entire cancer community, including those who are suffering from cancer,” said Jon Retzlaff, the chief policy officer at the American Association for Cancer Research.
Looking ahead, Retzlaff said, “The No. 1 thing is for us to see robust, sustained and predictable annual funding support for the National Institutes of Health. And, if we see that through NIH and through the National Cancer Institute, the programs that have been created through the cancer moonshot will be allowed to continue.”
Initiatives under Biden include changes that make screening and cancer care more accessible to more people, said Knudsen, with the American Cancer Society.
For instance, Medicare has started to pay for follow-up colonoscopies if a stool-based test suggests cancer, she said, and Medicare will now pay for navigation services to guide patients through the maze of their cancer care.
“You’ve already paid for the cancer research. You’ve already paid for the innovation. Now let’s get it to people,” Knudsen said.
She also said she'd like to see the next administration pursue a ban on menthol-flavored cigarettes, which she said could save 654,000 lives over the next 40 years.
Scientists now understand that cancer is not a single disease, but hundreds of diseases that respond differently to different treatments. Some cancers have biomarkers that can be targeted by existing drugs that will slow a tumor’s growth. Many more targets await discovery.
“We hope that the next administration, whoever it may be, will continue to keep the focus and emphasis on our national commitment to end cancer as we know it,” said Dr. Crystal Denlinger, CEO of the National Comprehensive Cancer Network, a group of elite cancer centers.
